It's the structured path a molecule follows from lab to market: preclinical research, Phase I (safety), Phase II (efficacy and dosing), Phase III (large-scale confirmation), regulatory review, and Phase IV post-market monitoring. As of 2026, nearly half of the roughly 23,000 active global pipeline drugs are still in the preclinical stage alone.
Discover how AI, real-time API intelligence, phases of pharmaceutical development, and API clinical trial data are transforming pharmaceutical supply chains through smarter forecasting, risk management, and strategic decision-making.
Learn how predictive supplier insights help prevent API shortages by identifying risks early, improving sourcing decisions, and ensuring supply continuity.
Here is a number that should stop you: more than 10,000 rare diseases have been identified globally, yet fewer than 500 have an approved treatment.
This is why more pharmaceutical companies are investing in unified intelligence platforms that centralize data, improve visibility, and support better decision-making across the drug development lifecycle.
Discover how early-phase pipeline tracking helps pharmaceutical companies identify high-value licensing opportunities, assess risks, and gain competitive advantage.
Backed by latest FDA data, this article analyzes approval trends, clinical challenges, and innovation drivers in pharmaceutical R&D.
Oncology is printing money. There is no other therapy area in global pharma that even comes close to the numbers being put up by cancer drugs right now.
This post isn't about defining what pipeline intelligence is. It's about what it does, specifically, the seven strategic advantages it gives pharma manufacturers who choose to act on it rather than admire it from a distance.
India makes a lot of medicine. A LOT. It ships pills, syrups, and injections to more than 200 countries.
8 July 2026
3 July 2026
23 June 2026
17 June 2026
8 June 2026
